Copd Newswire

Copd Newswire

Comprehensive Real-Time News Feed for Copd.

Results 1 - 20 of 163 in Copd

  1. Cannabis Science Invests In The Research And Development Of...Read the original story

    Yesterday | BioSpace

    Cannabis Science, Inc. , a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has invested in the research and development of new cannabinoid-based medications to treat Chronic Obstructive Pulmonary Disease and Asthma. According to the Centers for Disease Control and Prevention, in the U.S. alone over 15 million people have been diagnosed with COPD, and over 25 million with Asthma.

    Comment?

  2. Verona Pharma Receives Regulatory Approval to Commence Phase 2b...Read the original story

    14 hrs ago | World News Report

    ... for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD). The trial is expected to commence in the third quarter of 2017, with top-line data expected in the second half of 2018. RPL554 is ...

    Comment?

  3. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    17 hrs ago | Business Wire

    ... is providing fans with a look into Tony Stewart's first year as full-time co-owner of Stewart-Haas Racing. )--The COPD Foundation today announced the launch of the COPD and Pneumonia Study (CAP), a research initiative designed to describe the burden ...

    Comment?

  4. COPD Foundation Launches COPD and Pneumonia Study to Recognize the Burden of Pneumonia on PatientsRead the original story w/Photo

    Yesterday | Business Wire

    COPD, a progressive lung disease characterized by wheezing and breathlessness, affects 30 million Americans. An acute lung infection, such as pneumonia, is potentially fatal for those living with COPD.

    Comment?

  5. Smart Inhalers Industry : Set for Expansion in 2022Read the original story w/Photo

    Friday Jun 23 | SBWire

    ... patients to take their inhaler dose at the required time due to which it has emerged as a novel approach in asthma and COPD management. The major factors that drives the smart inhalers market include worldwide growth in population susceptible to ...

    Comment?

  6. Smart Inhalers Industry 2017 Market Insights, Opportunities,...Read the original story w/Photo

    Wednesday Jun 21 | SBWire

    ... the factors boosting the market growth. However, lesser availability of smart inhalers, high expenditure of asthma and COPD treatment, and resistance towards adoption of smart inhalers are hindering the market growth. North America is projected to ...

    Comment?

  7. Worldwide Asthma and COPD Drug Market 2017- Strategy Resources, Manufacturers, Supply to 2022Read the original story w/Photo

    Wednesday Jun 21 | SBWire

    New report on Asthma and COPD Drug are chronic diseases characterized by airway obstruction in the lungs causing respiratory infection and fatigue. COPD is characterized by yellow phlegm in the cough and episodes of cough and wheezing at night are the characteristics of asthma.

    Comment?

  8. COPD Patients Struggle with More than Breathing DifficultiesRead the original story w/Photo

    Wednesday Jun 14 | Market Wire

    A new Health Union national survey, COPD In America 2017 , of more than 2,000 individuals diagnosed with chronic obstructive pulmonary disease reveals that patients struggle with a range of issues that go beyond difficulties with breathing. The survey was released through Health Union's online community, COPD.net, and finds patients struggle with the emotional impact of COPD and often find their healthcare providers are not very helpful in addressing these issues.

    Comment?

  9. Key Opportunities : Oxygen Therapy Devices Market - Global Industry...Read the original story w/Photo

    Monday Jun 12 | SBWire

    ... application area of oxygen therapy across various disease conditions such as chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea, and respiratory distress syndrome is driving the growth of the global oxygen therapy devices ...

    Comment?

  10. Rapid Infuser Device Market Research Report: Analysis & Trends 2024Read the original story w/Photo

    Thursday Jun 8 | SBWire

    ... chronic pulmonary diseases is accelerating market growth. According to new estimates by the World Health Organization, COPD is predicted to become the third leading cause of death by 2030. An estimated 64 million people were suffering from COPD in ...

    Comment?

  11. ndd Medical Technologies Introduces Easy ...Read the original story

    Wednesday Jun 7 | The Financial Mirror

    ... naturally gravitating to these devices." Every four minutes, a person dies from chronic obstructive pulmonary disease (COPD)1, the third leading cause of death in the U.S.2 With millions of people already diagnosed, an additional 12 million ...

    Comment?

  12. Even on Medicare, chronic lung patients struggle to pay for medicinesRead the original story w/Photo

    Tuesday Jun 6 | Philly.com

    Juanita Milton, who suffers from COPD, uses her nebulizer with albuterol sulfate at her home in Live Oak, Texas, on April 25, 2017. "Having COPD feels like drowning," Milton said.

    Comment?

  13. Many COPD Patients Struggle To Pay For Each Medicinal BreathRead the original story w/Photo

    Tuesday Jun 6 | Gilmer Mirror

    ... it so far." An estimated 1 in 9 Medicare beneficiaries are diagnosed with chronic obstructive pulmonary disease, or COPD. And, in 2014, COPD was the third-leading cause of death in the country, according to the U.S. Centers for Disease Control and ...

    Comment?

  14. Many COPD Patients Struggle To Pay For Each BreathRead the original story w/Photo

    Friday Jun 2 | New Hampshire Public Radio -

    ... it so far." An estimated 1 in 9 Medicare beneficiaries are diagnosed with chronic obstructive pulmonary disease, or COPD. And, in 2014, COPD was the third-leading cause of death in the country, according to the U.S. Centers for Disease Control and ...

    Comment?

  15. Study: Combining non-invasive ventilation and home oxygen therapy can ...Read the original story w/Photo

    May 26, 2017 | Medical News

    ... (HOT) can significantly prolong time to readmission or death for patients with chronic obstructive pulmonary disease (COPD) following a life-threatening respiratory event or exacerbation. The five-year, multi-center study resulted in prolonged ...

    Comment?

  16. Philips sponsors research to help COPD patients breathe easierRead the original story w/Photo

    May 26, 2017 | Medical News

    ... (HOT) can significantly prolong time to readmission or death for patients with chronic obstructive pulmonary disease (COPD) following a life-threatening respiratory event or exacerbation. The five-year, multi-center study resulted in prolonged ...

    Comment?

  17. Mina LittrellRead the original story w/Photo

    May 25, 2017 | The Hutchinson News, Hutchinson Kansas

    ... at 10:30 a.m. at the Hugoton Cemetery. There is no visitation as cremation has taken place. Memorials are to the COPD Foundation in care of Swaim Funeral Chapel, P.O. Box 607, Sublette, KS 67877. HUGOTON - Mina Jayne Littrell, 69, died March 28, ...

    Comment?

  18. Symptoms Of COPD 5/23/17Read the original story

    May 23, 2017 | KTNV-TV Las Vegas

    Chronic Obstructive Pulmonary Disease affects approximately 30 million individuals in the United States, but there are warning signs you can be aware of. Stay alert for these notable signs and symptoms of COPD.

    Comment?

  19. Sunovion Announces Utibron Neohaler (Indacaterol/Glycopyrrolate)...Read the original story

    May 22, 2017 | BioSpace

    ... and night-time symptoms compared to placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), were presented at the 2017 American Thoracic Society International Conference (ATS 2017) held May 19-24, 2017, in ...

    Comment?

  20. Sunovion Presents Phase III Data Showing Safety, Efficacy And...Read the original story

    May 22, 2017 | BioSpace

    "With its efficacy and tolerability profile as well as the portability and short administration time, SUN-101/eFlowA could be a valuable treatment option for patients with COPD." "There are no approved nebulized, long-acting muscarinic antagonists currently available for use in COPD," said Thomas H. Goodin, Ph.D., Senior Director, Clinical Development at Sunovion.

    Comment?